When the dust settles from the collapse of Silicon Valley Bank, commentators and pundits will make proclamations about the cause and impact of SVB’s implosion. While the dust is still rising, we have an opportunity to reflect on both the clear and the less obvious governance and risk issues surrounding the SVB ecosystem and glean lessons which can be applied to every board, regardless of industry.
Speakers
Jane Sadowsky (Moderator)
Director, Yamana Gold and Nexa Resources
Christine Gorjanc
Director, Carbon Health, Invitae, Juniper Networks, and Zymergen
Louis Lehot
Partner, Foley & Lardner LLP
Gary Zimmerman
Managing Partner, Six Trees Capital LLC
People
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.